- Home
- CNTA vs SUPN Comparison
CNTA vs SUPN Comparison
Compare CNTA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- SUPN
- Stock Information
- Founded
- CNTA 2020
- SUPN 2005
- Country
- CNTA United Kingdom
- SUPN United States
- Employees
- CNTA 86
- SUPN N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- SUPN Health Care
- Exchange
- CNTA Nasdaq
- SUPN Nasdaq
- Market Cap
- CNTA 1.6B
- SUPN 1.9B
- IPO Year
- CNTA 2021
- SUPN 2012
- Fundamental
- Price
- CNTA $12.43
- SUPN $32.28
- Analyst Decision
- CNTA Strong Buy
- SUPN Hold
- Analyst Count
- CNTA 11
- SUPN 2
- Target Price
- CNTA $27.00
- SUPN $36.00
- AVG Volume (30 Days)
- CNTA 1.2M
- SUPN 529.3K
- Earning Date
- CNTA 08-12-2025
- SUPN 08-05-2025
- Dividend Yield
- CNTA N/A
- SUPN N/A
- EPS Growth
- CNTA N/A
- SUPN N/A
- EPS
- CNTA N/A
- SUPN 1.11
- Revenue
- CNTA $15,000,000.00
- SUPN $667,997,000.00
- Revenue This Year
- CNTA N/A
- SUPN N/A
- Revenue Next Year
- CNTA N/A
- SUPN $12.02
- P/E Ratio
- CNTA N/A
- SUPN $29.32
- Revenue Growth
- CNTA 118.88
- SUPN 11.82
- 52 Week Low
- CNTA $8.46
- SUPN $25.55
- 52 Week High
- CNTA $19.09
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CNTA 47.36
- SUPN 48.28
- Support Level
- CNTA $11.77
- SUPN $31.56
- Resistance Level
- CNTA $13.06
- SUPN $33.15
- Average True Range (ATR)
- CNTA 0.70
- SUPN 0.92
- MACD
- CNTA 0.03
- SUPN -0.03
- Stochastic Oscillator
- CNTA 51.21
- SUPN 40.34
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.